Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines

British Journal of Cancer

Volumn 71, Issue 5, 1995, Pages 914-924

  Jackman, A L ^a   Kelland, L R ^a   Kimbell, R ^a   Brown, M ^a   Gibson, W ^a   Ahernel, G W ^a   Hardcastle, A ^a   Boyle, F T ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Drug resistance; Folylpolyglutamate synthetase; Polyglutamation; Reduced folate carrier; Thymidylate synthase; ZD1694

Indexed keywords

10 PROPARGYL 5,8 DIDEAZAFOLIC ACID; 2 [5 [[(1,2 DIHYDRO 3 METHYL 1 OXOBENZO[F]QUINAZOLIN 9 YL)METHYL]AMINO] 1 OXO 2 ISOINDOLINYL]GLUTARIC ACID; ENZYME INHIBITOR; FLOXURIDINE; FOLYLPOLYGLUTAMATE SYNTHASE; METHOTREXATE; QUINAZOLINE DERIVATIVE; RALTITREXED; THYMIDYLATE SYNTHASE; TRITIUM;

ANIMAL CELL; ARTICLE; CELL LINE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG METABOLISM; DRUG RESISTANCE; DRUG TRANSPORT; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; HUMAN CELL; ISOTOPE LABELING; LEUKEMIA CELL LINE; LYMPHOBLASTOID CELL LINE; MOUSE; NONHUMAN; OVARY CELL; PRIORITY JOURNAL;

ANIMAL; ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; COMPARATIVE STUDY; DEOXYURACIL NUCLEOTIDES; DRUG RESISTANCE; FEMALE; FOLIC ACID; FOLIC ACID ANTAGONISTS; HUMAN; KINETICS; LEUKEMIA L1210; LYMPHOCYTES; METHOTREXATE; MICE; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PEPTIDE SYNTHASES; POLYGLUTAMIC ACID; PROTEINS; QUINAZOLINES; SUPPORT, NON-U.S. GOV'T; THIOPHENES; THYMIDYLATE SYNTHASE; THYMINE NUCLEOTIDES; TUMOR CELLS, CULTURED;

EID: 0029031286     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1995.178     Document Type: Article

References (66)

1. AHERNE GW. HARDCASTLE A AND NEWTON R (1992). Measurement of human thymidylate synthase (hTS) in cell lines using ELISA. Ann. Oncol, 3 (Suppl. 5), 77.
2. AHERNE W, HARDCASTLE A AND JACKMAN AL. (1993). Radioimmunoassay of d l l P pools in L1210 cells following thymidylate synthase inhibition. Proc. Am. Assoc. Cancer Res., 34, 273.
3. ASSARAF YG, FEDER JN, SHARMA RC, WRIGHT JE, ROSOWSKY A, SHANE B AND SCHIMKE RT. (1992). Characterisation of the coexisting multiple mechanisms of methotrexate resistance in mouse 3T6 R50 fibroblasts. J. Biol. Chem., 267, 5776–5784.
4. BARKER AJ, BOYLE FT, JACKMAN AL, CALVERT AH, PEGG SJ AND HUGHES LR. (1991). In vitro activity of non-glutamate containing quinazoline-based thymidylate synthase inhibitors. Proc. Am. Assoc. Cancer Res., 32, 327.
5. BASKIN F, CARLIN SC, KRAUS P, FRIEDKIN M AND ROSENBERG RN. (1975). Experimental chemotherapy of neuroblastoma. Mol. Pharmacol., 11, 105–117.
6. I0-propargyl-5,8-dide-azafolic acid (ICl 198583). In Advances in Experimental Medicine and Biology, Vol. 338, Ayling JE, Nair MG and Baugh CM (eds) pp. 593-596. Plenum Press: New York.
7. BERGER, SH, JENH C-H, JOHNSON LF AND BERGER FG. (1985). Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol. Pharmacol., 28, 461–467.
8. BOYLE FT, MATUSIAK ZS, HUGHES LR, SLATER AM, STEPHENS TC, SMITH MN, KIMBELL R AND JACKMAN AL. (1993). Substituted-2-desamino-2-methyl-quinazolinones. A series of novel antitumour agents. In Advances in Experimental Medicine and Biology, Vol. 338, Ayling JE, Nair MG and Baugh CM (eds) pp. 585-588. Plenum Press: New York.
9. BURRIS III H, VON HOFF D, BOERN K, HEAVEN R, RINALDI D, ECKARDT J, FIELDS S, CAMPBELL L, ROBERT F, PATTON S AND KENNEALEY G. (1994). A phase II trial of ZD1694, a novel thymidylate synthase inhibitor, in patients with advanced nonsmall cell lung cancer. Ann. Oncol., 5 (Suppl. 5), 133.
10. 10-propargyl-5,8-dideazafolic acid, CB3717. J. Clin. Oncol., 4, 1245–1252.
11. CHABNER BA. ALLEGRA CJ, CURT GA. CLENDENIN NJ, BARAM J, KOIZUMI S, DRAKE JC AND JOUVET J. (1985). Polyglutamation of methotrexate. J. Clin. Invest., 76, 907–912.
12. CLARK JL, BERGER SH, MITTELMAN A AND BERGER FG. (1987). Thymidylate synthase gene amplification in a colon tumour resistant to fluoropyrimidine chemotherapy. Cancer Treat. Rep., 71, 261–265.
13. CLARKE SJ, JACKMAN AL, AND JUDSON IR, (1993). The history of the development and clinical use of CB3717 and ICI D1694. In Novel Approaches to Selective Treatments of Human Solid Tumours: Laboratory and Clinical Correlation, Vol. 339, Rustum Y (ed.) pp. 277-287. Plenum Press: New York.
14. CLARKE SJ, WARD J, DE BOER M, PLANTING A, VERWEU J, SUTCLIFFE F, AZAB M AND JUDSON IR. (1994). Phase I study of the new thymidylate synthase inhibitor Tomudex (ZD 1694) in patients with advanced malignancy. Ann. Oncol., 5 (Suppl. 5), 132.
15. COWAN KH AND JOLIVET J. (1984). A methotrexate-resistant human breast cancer cell line with multiple defects, including diminished formation of methotrexate polyglutamates. J. Biol. Chem., 259, 10793–10800.
16. CURTIN NJ, HARRIS AL AND AHERNE GW. (1991). Mechanism of cell death following thymidylate synthase inhibition: 2’-deoxyuridine-5’-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res., 51, 2346–2352.
17. DANENBERG KD AND DANENBERG PV. (1989). Activity of thymidylate synthetase and its inhibition by 5-fluorouracil in highly enzyme overproducing cells resistant to 10-propargyl-5,8-dide-azafolate. Mol. Pharmacol., 36, 219–223.
18. DUCH DS, BANKS S, DEV IK, DICKERSON SH, FERONE R, HEATH LS, HUMPHREYS J, KNICK V, PENDERGAST W, SINGER S, SMITH GK, WATERS K AND WILSON HR. (1993). Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase. Cancer Res., 53, 810–818.
19. FREEMANTLE SJ, LUNEC J, JACKMAN AL, KELLAND LR, AHERNE GW AND CALVERT AH. (1993). Molecular characterisation of three cell fines selected for resistance to folate-based thymidylate synthase inhibitors. Br. J. Cancer, 67 (Supp. XX), 79.
20. FRY DW AND JACKSON RC. (1986). Membrane transport alterations as a mechanism of resistance to anticancer agents. Cancer Surveys, 5, 47–51.
21. FRY DW, BESSERER JA AND BORITZKI TJ. (1984). Transport of antitumour antibiotic CI-920 into L1210 leukemia cells by the reduced folate carrier system. Cancer Res., 44, 3366–3370.
22. GALIVAN J. (1980). Evidence for the cytotoxic activity of polyglutamate derivatives of methotrexate. Mol. Pharmacol., 17, 105–110.
23. GIBSON W, BISSET GMF, MARSHAM PR, KELLAND LR, JUDSON IR AND JACKMAN AL. (1993). The measurement of polyglutamate metabolites of the thymidylate synthase inhibitor, ICI D1694, in mouse and human cultured cells. Biochem. Pharmacol., 45, 863–869.
24. GRINDEY GB. SHIH C. BARNETT CJ. PEARCE HL, ENGELHARDT JA, TODD GC. RNZEL SM, WORZALLA JF. GOSSETT LS, EVERSON TP, WILSON TM, KOBIERSKI ME. WINTER MA, BEWLEY JR. KUHNT D, TAYLOR EC AND MORAN RG. (1992). LY231514, a novel pyrrolopyrimidine antifolate that inhibits thymidylate synthase. Proc. Am. Assoc. Cancer Res., 33, 441.
25. GORE M, EARL H. CASSIDY J, TATTERSAL M, MANSI J AND AZAB M. (1994). Phase II study of Tomudex (ZD1694) in refractory ovarian cancer. Ann. Oncol., 5 (Suppl. 5), 133.
26. HILLS CA. KELLAND LR, ABEL G, SIRACKY J, WILSON AP AND HARRAP KR. (1989). Biological properties of ten human carcinoma cell lines: calibration in vitro against four platinum complexes. Br. J. Cancer, 59, 527–534.
27. HUGHES LR. JACKMAN AL. OLDFIELD J, SMITH RC, BURROWS KD. MARSHAM PR, BISHOP JAM, JONES TR, O’CONNOR BM AND CALVERT AH. (1990). Quinazoline antifolate thymidylate synthase inhibitors: alkyl, substituted alkyl, and aryl substituents in the C2 position. J. Med. Chem., 33, 3060–3067.
28. IMAM AMA, CROSSLEY PH, JACKMAN AL AND LITTLE PFR. (1987). Analysis of thymidylate synthetase gene amplification and of mRNA levels in the cell cycle. J. Biol. Chem., 262, 7368–7373.
29. 10-propargyl-5,8-dideazafolic acid (CB3717): development chracterisation and cross-resistance studies. Cancer Res., 46, 2810–2815.
30. 10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in LI210 in vivo. Cancer Res., 50, 5212- 5218.
31. JACKMAN AL, TAYLOR GA. GIBSON W, KIMBELL R, BROWN M, CALVERT AH. JUDSON IR AND HUGHES LR. (1991a). ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res., 51, 5579–5586.
32. JACKMAN AL. JODRELL DI, GIBSON W AND STEPHENS TC. (1991b). ICI D1694, an inhibitor of thymidylate synthase for clinical study. In Purine and Pyrimidine Metabolism in Man, Vol. VII, Part A. (RA Harkness and TB Elion, (eds) pp. 19-23. Plenum Press: New York.
33. 10-propargyl-5,8-dideazafolic acid (ICI 198583). Biochem. Pharmacol., 42, 1885–1895.
34. 10-substituted-5,8-dideazafolates. Adv. Enz. Regul., 31, 13–27.
35. JACKMAN AL. GIBSON W, BROWN M, KIMBELL R AND BOYLE FT. (1993a). The role of the reduced-folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D1694. In Novel Approaches to selective Treatments of Human Solid Tumors: Laboratory and Clinical Correlation, Vol. 339, Rustum Y (ed.) pp. 265-276. Plenum Press: New York.
36. 10-propargyl-5,8-dideazafolate as antitumour agents. In Advances in Experimental Medicine and Biology, Vol. 338, Ayling JE, Nair MG and Baugh CM. (eds) pp. 579-584. Plenum Press: New York.
37. JANSEN G, SCHORNAGEL JH, WESTERHOF GR, RUKSON GR, NEWELL DR AND JACKMAN AL. (1990). Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors. Cancer Res., 50, 7422 -7548.
38. JENH C-H, GEYER PK, BASKIN F AND JOHNSON LF. (1985). Thymidylate synthase gene amplification in fluorodeoxyuridine-resistant mouse cell lines. Mol. Pharmacol., 28, 80–85.
39. JENNRICH RJ AND SAMPSON PF. (1968). Application of a step-wise regression to non-linear least squares estimation. Technometrics, 10, 63–72.
40. JOUVET J AND CHABNER BA (1983). Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. J. Clin. Invest., 72, 773–778.
41. JONES TR. CALVERT AH, JACKMAN AL, BROWN SJ, JONES M AND HARRAP KR. (1981). A potent antitumour quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice. Ear. J. Cancer, 17, 11–19.
42. JONES TR, THORNTON TJ, FLINN A, JACKMAN AL, NEWELL DR AND CALVERT AH. (1989). Quinazoline antifolates inhibiting thymidylate synthase: 2-desamino derivatives with enhanced solubility and potency. J. Med. Chem., 32, 847–852.
43. KOIZUMI S AND ALLEGRA CJ. (1992). Enzyme studies of methotrexate-resistant human leukemic cell (K562) subclones. Leukemia Res., 16, 565–569.
44. U WW, WALTHAM M, TONG W, SCHWEITZER BI AND BERTINO JR. (1993). Increased activity of y-glutamyl hydrolase in human sarcoma cell lines: a novel mechanism of intrinsic resistance to methotrexate. In Chemistry and Biology of Pteridines, Advances in Experimental Medicine and Biology, Vol. 338, Ayling JE, Nair MG and Baugh CM. (eds) pp. 635-638. Plenum Press: New York.
45. MCBURNEY MW AND WHITMORE GF. (1974). Isolation and Biochemical characterisation of folate-deficient mutants of Chinese Hamster Cells. Cell, 2, 173–182.
46. MCCLOSKEY DE, MCGUIRE JJ, RUSSELL CA. ROWAN BG, BERTINO JR, PIZZORNO G AND MINI E. (1991). Decreased folylpoly-glutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J. Biol. Chem., 6181–6187.
47. MARSHAM PR. HUGHES LR, JACKMAN AL, HAYTER AJ. OLDHELD J, WARDLEWORTH JM. BISHOP JA, O’CONNOR BM AND CALVERT AH. (1991). Quinazoline antifolate thymidylate synthase inhibitors: heterocyclic benzoyl ring modifications. J. Med. Chem., 34, 1594–1605.
48. 10-propargyl-5,8-dideazafolic acid (ICI 198583): a novel folate-based TS inhibitor. Cancer Res., 52, 1137–1143.
49. PAVLOVIC M, LEFFERT JJ, RUSSELLO O, BUNNI MA, BEARDSLEY GP, PRIEST DG AND PIZZORNO G. (1993). Altered transport of folic acid and antifolates through the carrier-mediated reduced folate transport system in a human leukemia cell fine resistant to (6R) 5,10-dideazatetrahydrofolic acid (DDATHF). In Advances in Experimental Medicine and Biology, Vol. 338, Ayling JE, Nair MG and Baugh CM. (eds) pp. 775-778. Plenum Press: New York.
50. PIALL EM, CURTIN NJ, AHERNE GW, HARRIS AL AND MARKS V. (1989). The quantitation by radioimmunoassay of 2’deoxyuridine-5’-triphosphate in extracts of thymidylate synthase inhibited cells. Anal. Biochem., 177, 347–352.
51. PIZZORNO G, MINI E, CORONNELLO M, MCGUIRE JJ, MOROSON BA, CASHMORE AR, DREYER RN, LIN JT, MAZZEI T, PERITI P AND BERTINO JR. (1988). Impaired polyglutamation of methotrexate as a cause of resistance in CCRF-CEM cells after shortterm, high-dose treatment with this drug. Cancer Res., 48, 2149–2155.
52. PIZZORNO G, CHANG Y-M, MCGUIRE JJ AND BERTINO JR. (1989). Inherent resistance of human squamous carcinoma cell lines to methotrexate as a result of decreased polyglutamation of this drug. Cancer Res., 49, 5275–5280.
53. PRIEST DG, LEDFORD BE AND DOIG MT. (1980). Increased thymidylate synthetase in 5-fluorodeoxyuridine-resistant cultured hepatoma cells. Biochem. Pharmacol., 29, 1549–1553.
54. RAYNAUD F, HARDCASTLE A AND AHERNE W. (1993). Sensitive measurement of dUMP by radioimmunoassay. Br. J. Cancer, 67 (Suppl. XX), 62.
55. RHEE MS, WANG Y, NAIR MG AND GALIVAN J. (1993). Acquisition of resistance to antifolates caused by enhanced y-glutamyl hydrolase activity. Cancer Res., 53, 2227–2230.
56. ROSS ANA C, RAO LG AND JOHNSON LF. (1982). Thymidylate synthase overproduction in 5-fluorodeoxyuridine-resistant mouse fibroblasts. Mol. Cell. Biol., 2, 1118–1125.
57. SAMUELS LL, GOUTAS LJ, PRIEST DG, PIPER JR AND SIROTNAK FM. (1886). Hydrolytic cleavage of methotrexate y-polyglutamates by folylpolyglutamyl hydrolase derived from various tumours and normal tissues of the mouse. Cancer Res., 46, 2230–2235.
58. SANGHANI PC, JACKMAN A. EVANS VR, THORNTON T, HUGHES L, CALVERT AH AND MORAN RG. (1994). A strategy for the design of membrane-permeable folyl-f-glutamate synthetase inhibitors: ‘Bay-region’-substituted 2-desamino-2-methyl-5,8-dide-azafolate analogs. Mol. Pharmacol., 45, 341–351.
59. 0-propargyl-5,8-dideazafolic acid (CB3717) polyglutamates in L1210 Cells in vitro. Biochem. Pharmacol., 37, 4047–4054.
60. SKELTON LA. KIMBELL R, BRUNTON LA. BOYLE FT AND JACKMAN AL (1994). 2-pyridyl quinazolines as inhibitors of thymidylate synthase. Proc. Am. Assoc. Cancer Res., 35, 301.
61. SMITH, IE, SPIELMAN M, BONNETERRE J, NAMER M, GREEN M, WANDER HE, TOUSSAINT C AND AZAB M. (1994). Tomudex (ZD1694), a new thymidylate synthase inhibitor with antitumour activity in breast cancer. Ann. Oncol., 5 (Suppl. 5), 132.
62. SZETO DW, CHENG YC, ROSOWSKY A, YU C-S, MODEST EJ, PIPER JR, TEMPLE C. ELLIOTT RD, ROSE JD AND MONTGOMERY JA. (1979). Human thymidylate synthase-III. Biochem. Pharmacol., 28, 2633–2637.
63. VAN DER LAAN BFAM, JANSEN G, KATHMANN I, SCHORNAGEL JH AND HORDUK GJ. (1991). Mechanisms of acquired resistance to methotrexate in a human squamous carcinoma cell line of the head and neck, exposed to different drug schedules. Eur. J. Cancer, 27, 1274–1278.
64. WARD WHJ, KIMBELL R AND JACKMAN AL. (1992). Kinetic characteristics of ICI D1694: a quinazoline antifolate which inhibits thymidylate synthase. Biochem. Pharmacol., 43, 2029 -2031.
65. WEBBER SE, BLECKMAN TM, ATTARD J AND 18 OTHERS. (1993). Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and biological evaluation of a novel class of 5-substituted quinazolinones. J. Med. Chem., 36, 733 -746.
66. ZALCBERG J, CUNNINGHAM D, VAN CUTSEM E, FRANCOIS E. SCHORNAGEL JH, ADENIS A. GREEN M, STARKHAMMER H AND AZAB M. (1994). Good antitumour activity of the new thymidylate synthase inhibitor Tomudex (ZD1694) in colorectal cancer. Ann. Oncol., 5 (Suppl. 5), 133.